Creatine Kinase Elevation during Antithyroid Treatment of a Patient with Graves’ Disease: A Case Report and Review of Literature

Authors
B. Uçan1, C. Yüksek2, M. Kızılgul1, R. Erten2, G. Konuk2, Z. Mercan2, F. Atık2, F. Demir2, E. Cakal3

Affiliations

Key words
thyroid
Graves’ disease
antibodies

Abstract
Thionamides (methimazole and propylthiouracil), which have been used in the treatment of Graves’ disease since 1940, inhibit the organization of iodine and coupling of iodotyrosines, thus blocking the synthesis of hormones. Myalgia is a rare side effect of these drugs. CK is the muscle specific kinase. The measurement of serum concentration of CK is useful to estimate the muscles’ breakdown. We present a young male patient with Graves’ disease who had abnormal increase of CK level during treatment with methimazole (MMI). He experienced myalgia and elevated CK level 1 month after initiation of MMI. In the beginning of the myalgia, his free T4 level decreased to normal range. After dose reduction of MMI, CK level decreased and his symptoms were resolved. Although the mechanisms for this effect are not yet clear, it is thought that rapid decrease in thyroid hormone by antithyroid treatment in susceptible patients with Graves’ disease can be the cause of CK elevation. Measuring CK level in Graves disease patients presented with myalgia during treatment with antithyroid drugs would be a useful diagnostic tool.

Introduction
Graves’ disease is characterized by excessive production of hormones by the diffusely enlarged thyroid gland as a result of thyroid-stimulating antibodies, which bind to and activate the thyrotropin receptor on thyroid cells. Thionamides (methimazole and propylthiouracil), which are used in the treatment of Graves’ disease, inhibit the organization of iodine and coupling of iodotyrosines, thus blocking the synthesis of hormones [1]. Minor side effects of thionamides are pruritis, cutaneous rash, urticaria, fever, arthralgia, nausea, sickness and olfaction disorders, and occur in 1–5% of patients. Minor side effects can resolve spontaneously; in case of persistence, the administered thionamide can be replaced by another available drug. Major side effects are agranulocytosis, hepatotoxicity, aplastic anemia and vasculitis, and occur in approximately 0.2–0.5% of the cases [2]. Myalgia is a rare side effect these drugs. We present a case of creatinine kinase elevation shortly after initiating metimazole, continued after switching to propylthiouracil (PTU) and resolved with dose reduction.

Case Presentation
A 32 year old male patient who has been previously healthy, on no medications, presented for palpitation, hand tremors, easy fatigability and 14 kg weight loss during last 2 months. His serum TSH level was < 0.005 µIU/mL (normal range (NR): 0.27–4.2 µIU/mL), free T3 (FT3) level was 16.53 pg/dL (NR: 2.6–4.8 pg/dL), free T4 (FT4) level was 3.74 ng/dL (0.93–1.7 ng/dL) and creatine kinase (CK) was 54 U/L. Serum anti-thyroid peroxidase antibody was 132 IU/mL (NR: 0–34 IU/mL), anti thyroglobulin antibody was 772 IU/mL (NR: 0–115 IU/mL), thyroid stimulating immunoglobulin (TSI) was 32.72 U/L (NR: 0–14 U/L). An ultrasonogram of thyroid gland demonstrated decreased echogenicity and pseudonodular appearance and, doppler ultrasonogram revealed enhanced vascularization. The 24-h radioactive iodine uptake test as determined by a 131I thyroid scan was 48% (NR: 25–40). He was started on methimazole 20 mg/day and propranolol 40 mg/day. One week later his methimazole dose was decreased to 10 mg/day due to a decrease in neutrophil count. His neutropenia was resolved after dose reduction. One month later he began to...
experience weakness, severe muscle cramps and myalgia. CK determination was 3775 U/L (NR: 30–200 U/L) and his TSH level was 0.219 µIU/mL, FT4 level was 0.94 ng/mL, Ca level was 9.1 mg/dL (NR: 8.6–10.4 mg/dL), K level was 4.2 mEq/L (3.5–5.5 mEq/L), Mg level was 2.06 mg/dL (1.8–2.6 mg/dL). All other laboratory findings were normal (Table 1). An electromyography examination was normal. His methimazole (MMI) dose was tapered to 5 mg/day. 4 days later his symptoms resolved and his CK level reduced to 704 U/L but still remained elevated. Then MMI treatment was switched to propylthiouracil (PTU) 100 mg/day. He still noticed cramps and myalgia 10 days after beginning of PTU therapy, at which point the serum TSH was 1.78 µIU/mL, FT4 was 0.937 ng/mL and serum CK was 651 U/L. All other laboratory findings were normal. PTU therapy was stopped and MMI 2.5 mg/day started. One month later, his symptoms resolved and serum CK gradually normalized. Now, the patient is clinically stable on MMI 2.5 mg/day therapy.

Discussion

One of the frequently used medications for Graves’ disease is MMI. Common side effects of MMI include agranulocytosis, skin rash and arthralgia, and the incidence of myalgia is very rare. CK is the muscle specific kinase. The measurement of serum concentration of CK is useful to estimate the muscles’ breakdown. Our patient was in subclinical hyperthyroidism at the time of CK elevation. Other causes [3,4] of CK elevation such as hyperthyroidism, excessive physical exercise, neuromuscular disorders, myocardial infarction, stroke, epileptic seizures, repeated intramuscular injection, high fever, trauma, statin treatment, hypocalcemia and alkalois were unlikely in our patient. Thyrotoxic myopathy, usually involves proximal muscles of extremities, is painless and do not cause CK elevation [5]. Our patient had dramatically elevated CK, thus making this diagnosis unlikely. There are a number of case reports about antithyroid drug induced CK elevation in the literature. Shergy WJ et al. reported a case of a patient with polymyositis and high CK levels after PTU treatment for hyperthyroidism but the authors failed to distinguish if the elevation CK was related to drug effect of PTU or polymyositis. The patients symptoms resolved after withdrawal of PTU and treatment with prednisone and metotrexate [2]. Suzuki et al. reported 4 cases of adult patients with Graves’ disease and an abnormal increase in serum CK concentrations during treatment with thionamides. The serum levels of CK were decreased after the reduction of the dose of MMI and adding levothyroxine to the treatment. The authors propounded that the rapid reduction in thyroid hormone causes a local hypothyroid state within the muscle tissue, which may have contributed to the CK elevations and they suggested that hasty correction of thyrotoxicosis should be avoided in susceptible patients, unless thyrotoxic conditions are critical such as cardiac failure or thyrotoxic crisis. They also mentioned that the direct effect of the agents to muscle or immunosuppressive action of drugs may have a role in thionamide induced CK elevation [6]. Mizuno described 2 cases of increases in serum CK concentrations in children undergoing treatment of Graves’ disease with antithyroid medications. Both patients were euthyroid at the time of CK elevation. Authors speculated that the acute decrease of thyroid hormones in tissues following a state of chronic hyperthyroidism may result in relative hypothyroid states and subsequent alterations in CK concentrations as Suzuki et al. mentioned before [7]. Khalil et al. reported a case of MMI-induced myositis that resolved after withdrawal of the offending drug [8]. Chieh-Hua Lu described 2 cases presented with complaints of myalgia and muscle cramps, and serum CK elevation a few weeks after initiation of antithyroid treatment. The patients were in subclinical hyperthyroidism at the time of CK elevation. The authors propounded that acute decrease of thyroid hormones or blocking of the actions of deidinase may play a role in CK elevation [9]. Kim H et al. reported a 13 year old patient with Graves disease who developed myalgia and elevated CK level after MMI treatment. After decrease in MMI dose and adding levothyroxine, her CK level reduced to normal range and her myalgia was resolved. They speculated that CK elevation could be a direct influence of antithyroid medications on muscle or a rapid decline in thyroid hormone level [10]. Ito T et al. reported a case with CK elevation during treatment with antithyroid drug. Adding levothyroxine to the treatment regimen was effective in their patient [11]. According to Suzuki et al., a rapid reduction of thyroid hormones regardless of mechanism is the cause of muscle symptoms and elevation of serum CK concentrations. This hypothesis is sug-

Table 1  Labaratory values of the patient.

<table>
<thead>
<tr>
<th>Laboratory tests</th>
<th>At diagnosis of hyperthyroidism</th>
<th>1 month after starting methimazole (10 mg/d)</th>
<th>1 week after tapering the dose of methimazole (5 mg/d)</th>
<th>10 days later methimazole switching to PTU 100 mg/d</th>
<th>1 month after methimazole 2.5 mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (0.27–4.2 µIU/mL)</td>
<td>&lt;0.005</td>
<td>0.219</td>
<td>0.672</td>
<td>1.78</td>
<td>1.749</td>
</tr>
<tr>
<td>FT3 (2.6–4.8 pg/dl)</td>
<td>16.53</td>
<td>2.83</td>
<td>2.78</td>
<td>3.18</td>
<td>3.03</td>
</tr>
<tr>
<td>FT4 (0.93–1.7 ng/dl)</td>
<td>3.74</td>
<td>0.94</td>
<td>0.951</td>
<td>0.937</td>
<td>1.06</td>
</tr>
<tr>
<td>Anti thyroglobulin (0–115 U/mL)</td>
<td>772</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Anti TPO (0–34 IU/mL)</td>
<td>132</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>TSI (0–14 U/L)</td>
<td>32.72</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CK (30–200 U/L)</td>
<td>54</td>
<td>3.775</td>
<td>704</td>
<td>651</td>
<td>106</td>
</tr>
<tr>
<td>AST (5–34 U/L)</td>
<td>15</td>
<td>30</td>
<td>20</td>
<td>18</td>
<td>19</td>
</tr>
<tr>
<td>ALT (0–55 U/L)</td>
<td>19</td>
<td>16</td>
<td>16</td>
<td>12</td>
<td>18</td>
</tr>
<tr>
<td>LDH (125–220 U/L)</td>
<td>–</td>
<td>–</td>
<td>199</td>
<td>181</td>
<td>310</td>
</tr>
<tr>
<td>WBC (4000–10000)</td>
<td>5700</td>
<td>4800</td>
<td>5800</td>
<td>5900</td>
<td>6100</td>
</tr>
<tr>
<td>Neuron count (500–1500)</td>
<td>3300</td>
<td>2600</td>
<td>3000</td>
<td>3100</td>
<td>3580</td>
</tr>
</tbody>
</table>

AST, aspartate transaminase; ALT, alanine aminotransferase; TSI, thyroid stimulating immunglobulin; Anti TG, anti thyroglobulin antibody; Anti TPO, anti-thyroid peroxidase antibody; WBC, white blood cell count; CK, creatine kinase
gested by Hernán Martínez J et al. They mentioned that thyroid hormone is important for the expression of fast myofibrillar proteins in the muscle. In hypothyroidism the expression of these proteins are deficient and there is an increase accumulation of slow myofibrillar proteins. They reported a case of rapid or abrupt decrease in thyroid hormones caused by radiiodine therapy after prolonged hyperthyroidism can lead to local hypothyroid state within the muscle tissue, resulting in CK elevation and hypothyroid myopathy [12]. As an opposing view, if this hypothesis is true CK elevation must be seen in more people with Graves’ disease treated with thionamides. In light of these information, it can put forward that abrupt decrease in thyroid hormone level with thionamides in susceptible host may have a role in CK elevation.

Serum creatine kinase is often increased and correlates with the severity of hypothyroidism [13]. Our patient had CK elevation without hypothyroidism during treatment. At the time of CK elevation his FT4 level was at the lower limit of normal so this situation can suggest the hypothesis described above.

In conclusion, CK elevation with complaints of myalgia and cramps can be seen as a rare side effect of antithyroid drug treatment in patients with hyperthyroidism due to Graves’ disease and it may be diminished with antithyroid dose reduction. These complications can be an indication for radiiodine therapy in Graves disease patients treated with antithyroid drugs. Although the mechanisms for this effect are not yet clear, it is thought that rapid decrease in thyroid hormone by antithyroid treatment in susceptible patients with Graves’ disease can be the cause of CK elevation. Measuring CK level in Graves disease patients presented with myalgia during treatment with antithyroid drugs would be a useful diagnostic tool.

Disclosure statement: The authors have nothing to disclose.

References
3 Pelle A, Tancredi L, Sciacco M, Chiveri L, Comi GP, Battistel A. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol 2002; 249: 305–311